965 related articles for article (PubMed ID: 12912965)
1. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
2. Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity.
Kim YH; Lee YJ
J Cell Biochem; 2006 Aug; 98(5):1284-95. PubMed ID: 16514644
[TBL] [Abstract][Full Text] [Related]
3. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
5. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway.
Nam SY; Amoscato AA; Lee YJ
Oncogene; 2002 Jan; 21(3):337-46. PubMed ID: 11821946
[TBL] [Abstract][Full Text] [Related]
6. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
7. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
8. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.
Hao C; Beguinot F; Condorelli G; Trencia A; Van Meir EG; Yong VW; Parney IF; Roa WH; Petruk KC
Cancer Res; 2001 Feb; 61(3):1162-70. PubMed ID: 11221847
[TBL] [Abstract][Full Text] [Related]
9. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Song JH; Bellail A; Tse MC; Yong VW; Hao C
J Neurosci; 2006 Mar; 26(12):3299-308. PubMed ID: 16554480
[TBL] [Abstract][Full Text] [Related]
10. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
Song JH; Song DK; Herlyn M; Petruk KC; Hao C
Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
[TBL] [Abstract][Full Text] [Related]
12. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
Mirandola P; Ponti C; Gobbi G; Sponzilli I; Vaccarezza M; Cocco L; Zauli G; Secchiero P; Manzoli FA; Vitale M
Blood; 2004 Oct; 104(8):2418-24. PubMed ID: 15205263
[TBL] [Abstract][Full Text] [Related]
13. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
14. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage.
Ramp U; Caliskan E; Mahotka C; Krieg A; Heikaus S; Gabbert HE; Gerharz CD
Br J Cancer; 2003 Jun; 88(11):1800-7. PubMed ID: 12771998
[TBL] [Abstract][Full Text] [Related]
16. Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation.
Bachmann F; Buechner SA; Wernli M; Strebel S; Erb P
J Invest Dermatol; 2001 Jul; 117(1):59-66. PubMed ID: 11442750
[TBL] [Abstract][Full Text] [Related]
17. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
18. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells.
Clodi K; Wimmer D; Li Y; Goodwin R; Jaeger U; Mann G; Gadner H; Younes A
Br J Haematol; 2000 Nov; 111(2):580-6. PubMed ID: 11122106
[TBL] [Abstract][Full Text] [Related]
19. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
Sylvester PW; Shah S
Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
[TBL] [Abstract][Full Text] [Related]
20. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Poulaki V; Mitsiades CS; McMullan C; Fanourakis G; Negri J; Goudopoulou A; Halikias IX; Voutsinas G; Tseleni-Balafouta S; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):358-66. PubMed ID: 15623796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
